{"url":"https://newsforagent.com/news/2026-11-18/recursion-fda-phase-3-fap-trial","markdown_url":"https://newsforagent.com/news/2026-11-18/recursion-fda-phase-3-fap-trial.md","title":"Recursion Wins FDA Alignment on Phase 3 FAP Trial","headline":"Recursion Aligns With FDA on Phase 3 Trial Design for REC-4881 in FAP","description":"Recursion secured FDA alignment on a Phase 3 trial design for REC-4881 in FAP, with a novel primary endpoint and enrollment of about 200 patients planned for 2027.","section":"Regulation & Approvals","published_at":"2026-11-18T10:14:48+00:00","modified_at":"2026-11-18T10:14:48+00:00","author":"News Desk","key_takeaways":["Recursion aligned with the FDA on a registrational Phase 3 trial design for REC-4881 in familial adenomatous polyposis.","The trial's primary endpoint counts excision of adenomas 10 mm or larger in the upper or lower GI tract as an event.","The randomized, double-blind, placebo-controlled trial is expected to enroll approximately 200 adults and begin in the second half of 2027.","Updated TUPELO data presented on November 2, 2026 showed a 47% median reduction in total polyp burden after 12 weeks."],"companies":[{"name":"Recursion Pharmaceuticals","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00007ed/recursion-pharmaceuticals","website":"https://www.recursion.com"}],"source":{"publisher":"GlobeNewswire","title":"Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis","url":"https://www.globenewswire.com/news-release/2026/11/18/3405436/0/en/recursion-announces-alignment-with-fda-on-registrational-phase-3-trial-design-for-rec-4881-in-familial-adenomatous-polyposis.html"},"other_sources":[],"tags":["Regulation & Approvals","Recursion Pharmaceuticals"],"body_markdown":"Recursion said on November 18, 2026 that it aligned with the FDA on the design of a registrational Phase 3 trial of REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis, a disease with no approved pharmacologic therapies. The [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/18/3405436/0/en/recursion-announces-alignment-with-fda-on-registrational-phase-3-trial-design-for-rec-4881-in-familial-adenomatous-polyposis.html) announcement said the trial is on track to begin in the second half of 2027.\n\n## How the REC-4881 Phase 3 Trial Is Designed\n\n[Recursion Pharmaceuticals](https://akta.pro/company-profiles/00007ed/recursion-pharmaceuticals) is a clinical-stage company that uses AI and proprietary biological data to discover drugs, with headquarters in Salt Lake City. REC-4881 was identified through unbiased phenotypic screening using Recursion's AI foundation models, and the company said it is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies.\n\nThe trial is a randomized, double-blind, placebo-controlled, event-driven study expected to enroll approximately 200 patients aged 18 and older who have had a colectomy or proctocolectomy. It will evaluate REC-4881 at a dose of 4 mg, with the dosing schedule to be determined from data emerging from the ongoing TUPELO trial, and will include a prespecified interim analysis.\n\nThe primary endpoint is event-free survival, counting the excision of an adenoma 10 mm or larger in either the upper or lower GI tract, prespecified criteria for multiple types of FAP-related surgery, high-grade dysplasia or cancer, or death from any cause. Modified Spigelman stage progression and total polyp burden are secondary endpoints.\n\n\"Securing FDA alignment on a novel component of our primary endpoint - counting the removal of adenomas 10 mm or larger across both the upper and lower GI tract as events - is a key milestone,\" said Najat Khan, Ph.D., President and Chief Executive Officer of Recursion.\n\n## Recursion's Funding and Leadership Record\n\nRecursion appointed Najat Khan as CEO and President effective January 1, 2026, with co-founder Chris Gibson moving to Chairman, according to akta.pro [company records](https://akta.pro/company-data). The same records show a $200 million post-IPO equity round in October 2026 and a completed $688 million merger with Exscientia in November 2024, followed by a workforce reduction of about 20% to integrate operations.\n\n## Earlier REC-4881 Results and Board Change\n\nOn November 2, 2026, Recursion reported Phase 2 results for REC-4881 showing a 47% median reduction in total polyp burden after 12 weeks, Investing.com reported. The updated TUPELO data presented at CGA-IGC that day showed approximately 1 in 3 patients achieving reductions of 65% or more, with no new safety signals.\n\nRecursion appointed Fred Hassan as Chair of its Board effective October 31, 2026, GlobeNewswire reported, citing his four decades of pharmaceutical leadership including roles at Schering-Plough and Pharmacia.\n\n## When the Phase 3 Trial Starts\n\nThe registrational Phase 3 trial is expected to begin in the second half of 2027, with enrollment of approximately 200 adults with FAP following colectomy or proctocolectomy.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}